2008Chinese Journal of Clinical PharmacyRequires access

Comparison of clinical effects between rosiglitazone and pioglitazone in the treatment of type 2 diabetes of eldly patients

Jiao Sun

Open publisher page 0 citations

Abstract

AIM To compare the clinical effects of rosiglitazone with pioglitazone in the treatment of type 2 dia- betic patients.METHODS Sixty-four patients who had been treated with food control,exercise and fixed oral anti-dia- betic drugs for one month,but their fasting plasma glucose level was still over 7 mmol·L~(-1).They were randomized divid- ed into two groups.One was added with rosiglitazone,the other was added with pioglitazone.All of them were treated for 12 weeks.RESULTS After treatment for 12 weeks,①patient's fasting plasma glucose,postprandial plasma glucose, HbA_(?)c and insulin resistance index were significant decreased in both groups;②triglyceride and total cholesterol were decreased in pioglitazone group(P0.05),but those in rosiglitazone group were no significant reduction(P0.05);③high density lipoprotein-cholesterol was elevated in both groups(P0.05).CONCLUSION Rosiglitazone or pioglita- zone can be used to control blood glucose,but pioglitazone shows more efficiency on triglyceride control.

About this research paper

What this paper is about

AIM To compare the clinical effects of rosiglitazone with pioglitazone in the treatment of type 2 dia- betic patients.METHODS Sixty-four patients who had been treated with food control,exercise and fixed oral anti-dia- betic drugs for one month,but their fasting plasma glucose level was still over 7 mmol·L~(-1).They were randomized divid- ed into two groups.One was added with rosiglitazone,the other was added with pioglitazone.All of them were treated for 12 weeks.RESULTS After treatment for 12 weeks,①patient's fasting plasma glucose,postprandial plasma glucose, HbA_(?)c and insulin resistance index were significant decreased in both groups;②triglyceride and total cholesterol were decreased in pioglitazone group(P0.05),but those in rosiglitazone group were no significant reduction(P0.05);③high density lipoprotein-cholesterol was elevated in both groups(P0.05).CONCLUSION Rosiglitazone or pioglita- zone can be used to control blood glucose,but pioglitazone shows more efficiency on triglyceride control.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

AIM To compare the clinical effects of rosiglitazone with pioglitazone in the treatment of type 2 dia- betic patients.METHODS Sixty-four patients who had been treated with food control,exercise and fixed oral anti-dia- betic drugs for one month,but their fasting plasma glucose level was still over 7 mmol·L~(-1).They were randomized divid- ed into two groups.One was added with rosiglitazone,the other was added with pioglitazone.All of them were treated for 12 weeks.RESULTS After treatment for 12 weeks,①patient's fasting plasma glucose,postprandial plasma glucose, HbA_(?)c and insulin resistance index were significant decreased in both groups;②triglyceride and total cholesterol were decreased in pioglitazone group(P0.05),but those in rosiglitazone group were no significant reduction(P0.05);③high density lipoprotein-cholesterol was elevated in both groups(P0.05).CONCLUSION Rosiglitazone or pioglita- zone can be used to control blood glucose,but pioglitazone shows more efficiency on triglyceride control.

Key concepts: Pioglitazone, Rosiglitazone, Postprandial, Internal medicine, Medicine, Triglyceride, Endocrinology, Type 2 diabetes

Related papers

Back to paper searchBrowse research topicsOriginal source
Comparison of clinical effects between rosiglitazone and pioglitazone in the treatment of type 2 diabetes of eldly patients — Research Paper | ScholarLens